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Abstract 
Background: Aldehyde dehydrogenase 1 (ALDH1) activity has been implicated in the therapeutic drug resistance of 
many malignancies and has been widely used as a marker to identify stem-like cells, including in primary liver cancer. 
Cancer stem cells (CSCs) are thought to play a crucial role in cancer progression and metastasis. In order to clarify the 
validity of the rabbit VX2 liver cancer model, we questioned if it expresses ALDH1 as a potential marker of CSCs. Hepa-
tocellular carcinoma is a common malignancy worldwide and has poor prognosis. Most of the animal models used 
to study hepatocellular carcinoma are rodent models which lack clinical relevance. The rabbit VX2 model is a large 
animal model useful for preclinical and for developing drugs targeting cancer stem cells.
Materials and methods: We used flow cytometry to identify rabbit VX2 liver tumor cells that express ALDH1A1 
activity at a high level and confirmed the results with RT-PCR, immunohistochemical and western blot analyses. Fur-
ther, mRNA and protein expression analysis of tumor samples also express the markers for stemness like klf4, oct3/4, 
CD44 and nanog as well as the differentiation marker α-fetoprotein.
Results: We used Aldefluor flow cytometry-based assay to identify cells with high ALDH1 activity in the rabbit VX2 
liver cancer model.  We used the brightest 4.39 % of the total cancer cell population in our study. We performed semi-
quantitative as well as real time PCR to characterize the stemness derived from VX2 tumors and tissues from normal 
rabbit liver. We demonstrated that VX2 tumors have higher expression of cancer stem cell markers such as AlDH1A1 
and CD44 in comparison to normal rabbit liver cells. Additionally, real time PCR analysis of the same samples using 
syber-green demonstrated the significant change (p > 0.05) in the expression of genes. We validated the gene expres-
sion of the stemness markers by performing western blot and immunofluorescence. We showed that cancer stem cell 
markers (AlDH1A1, CD44) and the differentiation marker α-fetoprotein were upregulated in VX2 tumor cells. The same 
extent of upregulation was observed in stemness markers (klf4, oct3/4 and nanog) in VX2 tumors in comparison to 
normal rabbit liver.
Conclusion: The overall results of this study indicate that ALDH1 is a valid CSC marker for VX2 cancer. This finding 
suggests that the rabbit VX2 liver cancer model is useful in studying drug resistance in hepatocellular carcinoma and 
may be useful for basic and preclinical studies of other types of human cancer.
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Background
Hepatocellular carcinoma (HCC) ranks among the most 
common and deadly malignancies worldwide. The annual 
incidence of this disease is an estimated 6,00,000 to 1 
million the number of new cases per year is expected to 
increase over the next few decades because of the high 
incidence of chronic hepatitis C (HCV) and hepatitis B 
(HBV) viral infections. There is a large pool of people 
who are infected with HCV, HBV, or both in whom the 
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from areas where hepatocellular carcinoma is endemic, 
such as Southeast Asia and parts of Africa, to the west 
where perinatal HBV infection and exposure to envi-
ronmental carcinogens such as aflatoxin (in particular 
Aflatoxin B1) are common, is likely to continue. These 
factors are therefore likely to increase the incidence of 
HCC in the US [1]. Other factors influencing the inci-
dence of HCC in western societies include nonalcoholic 
fatty liver disease (NAFLD) and nonalcoholic steatohepa-
titis (NASH) [2]. Surgical removal of the liver cancer or 
liver transplantation is the most effective therapies for 
HCC. However, most patients present with unresect-
able disease due to poor liver function and not meeting 
transplantation criteria. Additionally, there is a paucity 
of donor organs for transplantation. Novel approaches to 
treating nonresectable HCC are available but are rarely 
curative, and the 3-year patient survival rate remains rel-
atively low (30–40 %) [3, 4].
Cancer stem cells (CSCs) have been identified as 
important mediators in leukemia [5], pancreatic [6], lung 
[7], breast [8] and hepatocellular carcinoma [9] among 
other malignancies. These cells typically constitute 1–5 % 
of the total tumor cell population, although some malig-
nancies, such as breast cancer and glioblastoma, have 
larger CSC populations (11–35  % and 5–30  %, respec-
tively) [10]. CSCs are putatively considered the primary 
cells responsible for tumor initiation, growth, and metas-
tasis [11–13].
CSCs are believed to have properties similar to their 
nonmalignant stem cell counterparts such as self-
renewal, anchorage-independent growth, and the poten-
tial for differentiation [14, 15] into heterogeneous tumors 
[16, 17]. CSCs are thought to be chemoresistant, which 
may explain why they are enriched in residual tumors 
and can, subsequently, mediate tumor recurrence follow-
ing cytotoxic chemotherapy [18, 19]. For these reasons 
CSCs are considered attractive chemotherapeutic targets.
The lack of consensus on definitive stem cell markers 
has compromised the ability to functionally character-
ize them. Despite these setbacks ALDH1 is emerging 
as a universal functional marker of choice for cancer 
stem and progenitor cells [20]. The enzymatic activity 
of aldehyde dehydrogenase 1 (ALDH1) has been iden-
tified as one of the mechanisms for the resistance of 
progenitor cells to chemotherapeutic agents [21]. The 
ALDH1 family of enzymes are cytosolic isoenzymes 
that are responsible for oxidizing intracellular aldehydes 
and contributing to the oxidation of retinol to retinoic 
acid in early stem cell differentiation [22]. This enzy-
matic activity can be used to select for highly enriched 
populations of progenitor cells in bone marrow [23] and 
umbilical cord sources [24]. Recent studies have shown 
that ALDH1 is a CSC marker and that its presence 
strongly correlates with tumor malignancy as well as the 
self-renewal capacity of stem cells in tumors of the lung 
[25], breast [26], colon [27] and hepatocellular cancer 
(HCC) [28]. Stem cell activity of ALDH1 positive cells 
has been demonstrated in several different models of 
cancer such as mammary carcinoma [29], acute myeloid 
leukemia [30], pancreatic cancer [31], lung cancer [32], 
ovarian cancer [33] and hepatocellular carcinoma [34]. 
Our aim in the present study was to determine whether 
the rabbit orthotopic liver VX2 tumor model could be 
used as a model for human HCC. The presence of CSCs 
in rabbit VX2 tumors is hitherto unknown. The ortho-
topic VX2 tumor is a hypervascular tumor [35]. Using 
several techniques, we identified ALDH1 activity and 
the presence of CSC-like cells in VX2 tumors, which 
suggested that this rabbit model may serve as a preclini-
cal model for investigation of therapeutic stem cell tar-




VX2 liver tumor cells from harvested tumors were 
cultured in DMEM-F12 medium (Gibco Invitrogen, 
Carlsbad, CA, USA) with 1 % penicillin and 1 % strepto-
mycin (Gibco invitrogen) in an incubator with normoxic 
atmosphere and 5  % CO2 at 37  °C. Single-cell suspen-
sions of tumor cells were prepared by mincing primary 
rabbit VX2 tumors with a razor blade, washing them, 
and digesting them in 0.1  % Type I and IV collagenase 
(Sigma-Aldrich, St. Louis, MO, USA) in DMEM-F12 at 
room temperature for 15–30 min. A pipette was used to 
break up clumps in the digested material, and the sus-
pension was visually inspected under a light microscope 
to confirm that most cells had been released. Remain-
ing clumps were removed by filtration through a 40-μM 
nylon mesh screen.
Animals and tumor induction
The studies performed on live animals were approved 
by the Institutional Animal Care and Use Committee at 
the University of Texas MD Anderson Cancer Center. 
Ten adult New Zealand white rabbits (mean weight, 
4.04 ± 0.31 kg) were purchased from Charles River Lab-
oratories (Wilmington, MA). The animals were main-
tained in facilities accredited by the Association for 
Assessment and Accreditation of Laboratory Animal 
Care International and in accordance with regulations 
and standards of the U.S. Department of Agriculture, the 
U.S. Department of Health and Human Services, and the 
National Institutes of Health.
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Anesthesia and antibiotics
Anesthetic induction was achieved using isoflurane 
(0.5–5  %)/oxygen (1.5 L/min) administered via mask. 
Maintenance anesthesia was accomplished using iso-
flurane (0.5–5  %)/oxygen (1.5 L/min) administered via 
mask or, in some cases, an endotracheal tube. Thermal-
regulation was maintained for anesthetized animals 
using a Bair Hugger warming blanket. One peri-opera-
tive dose of antibiotics (enrofloxacin; 5 mg/kg) was given 
I.M.
Analgesics
Each rabbit receives a single dose of SR buprenorphine 
pre-operatively (0.1–0.3  mg/kg, followed by PRN/every 
72  h as determined by clinical veterinarian). Animals 
were assessed daily and analgesics were continued for as 
long as necessary to control pain.
For tumor implantation, each animal was pre-medi-
cated with an intramuscular injection of buprenorphine 
(0.15  mg/kg body weight; Bedford Laboratories, Bed-
ford, OH, USA), and a surgical plane of anesthesia was 
maintained using isoflurane. After routine surgical prep-
aration, the left lateral lobe of the liver was isolated fol-
lowing a mid-line abdominal incision. A 2–4 mm section 
of the donor VX2 tumor was surgically implanted in a 
focal spot in the left lateral liver lobe [4, 5].
Aldefluor assay
To isolate cells with high ALDH1 enzymatic activity, we 
used the Aldefluor kit (Cat. No. 1700, Stem Cell Tech-
nologies, Vancouver, BC), which is designed for opti-
mal identification and isolation of stem cells through 
specific interactions with human ALDH1 (90 % identity 
with rabbit ALDH1 with the nucleotide-nucleotide blast 
sequence alignment) (Ginestier, 2007). Cells were stained 
with Aldefluor reagent and quantified by flow cytometry. 
The experiments were carried out according to the man-
ufacturer’s instructions. Each experiment was repeated 
three times. Fresh cells were stained with 1  g/mL 
propidium iodide (PI; Sigma) for 5  min to determine 
viability. The gate for ALDH-positive cells were based on 
diethylaminobenzaldehyde (DEAB)-mediated inhibition 
of ALDH1, and the gate for viable cells was based on PI 
exclusion.
Real‑time PCR analysis (mRNA expression)
Total RNA was extracted using Qiagen’s RNeasy mini 
kit (Cat No. 74104). For preparation of cDNA, we fol-
lowed the protocol recommended by BioRad (iScriptTM 
cDNA Synthesis Kit, Cat No. 170-8890) by using 500 ng 
RNA from each sample. Real time PCR analysis was per-
formed using SsoFastTM EvaGreen Supermix (BioRad Cat 
no. 172-5200). The following primers were analyzed for 
mRNA expression as shown in (Table 1).
Immunohistochemical analysis
A fluorescence-activated cell sorting (FACS)-selected 
population of ALDH1-positive VX2 cells were fixed 
with 4  % paraformaldehyde for 15  min and blocked in 
10 % normal serum for 30 min. The cells were incubated 
with primary anti- Aldh1a1 (Catalog No. # ab23375); 
CD44 (Catalog No. #ab6124, abcam) and α-fetoprotein 
(Catalog No.3 2019-08, DAKO) at a working dilution of 
1:200, overnight at 4  °C. The cells were then incubated 
for 1  h with Alexa Fluor-conjugated (anti rabbit) sec-
ondary antibody in the dark at 37  °C. Cells were coun-
terstained with 4′,6-diamidino-2-phenylindole (DAPI) 
in mounting medium (Vector Laboratories, Inc., Burl-
ingame, CA, USA) to demonstrate the presence of nuclei. 
DAPI-stained negative controls were stained without the 
primary antibody. Stained cells were examined under a 
Nikon fluorescent microscope and a Zeiss LCM confocal 
microscope.
A sample of each tumor (induced as stated earlier) was 
fixed with 10 % neutral buffered formalin and embedded 
in paraffin for histopathologic examination. The cut sec-
tions (5–7 μm) were stained with hematoxylin and eosin 
using standard protocols.
Table 1 Primer pairs of RT-PCR experiment
Gene name NCBI reference sequence Primer sequence (forward 5′–3′) Primer sequence (reverse 5′–3′) Product size (bp)
nanog XM_002712762.1 GCCAGTCGTGGAGTAACCAT TGTGCTGTGTTCTGGCTTTC 196
oct3/4 (Pou5f1) NM_001099957.1 GAGATTTGCAAAGCGGAGAC CGGTTACAGAACCACACA CG 188
CD44 FJ360436.1 CCACGTGGAGAAAAATGGTC- CACGTGCCCTTCTATGAACC 157
klf4 XM_008255400.1 TTCAACGACCTTCCTGAACC TCGGGGTAACCTGAAAACTG 184
Gapdh NM_001082253.1 AGGTCATCCACGACCACTTC GTGAGTTTCCCGTTCAGC C 202
Nestin XM_008264301.1 GTGAGTTTCCCGTTCAGC C CTCCACATCAGAAGCAGCAA 176
Aldh1a1 AY038801.1 CTACCATCAGGGCCAGTGTT CCCCTTCTTTCTTCCCACTC 209
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Western blot analysis
Whole-cell proteins were extracted from unsorted cells at 
70–80 %. Cells were subjected to lysis in a buffer contain-
ing 20 mmol/L Tris–HCl (pH 8.0), 137 mmol/L NaCl, 1 % 
Triton X-100, 1 mmol/L Na3VO4, and 2 mmol/L ethylen-
ediaminetetraacetic acid (EDTA) plus one complete Mini 
Protease Inhibitor Cocktail Tablet (Roche Diagnostics, 
Indianapolis, IN, USA) per 10  mL of lysis buffer. After 
we determined the protein concentration of each lysate 
with the Bradford assay [Bradford M1976], lysate samples 
containing 40 μg of whole-cell protein extract, 20 μg of 
ALDH-positive cell proteins, or 20 μg of ALDH-negative 
cell proteins were subjected to electrophoresis on sodium 
dodecyl sulfate–polyacrylamide gels (SDS-PAGE) [Lae-
mmli UK., 1970] at a 10  % concentration (based on 
target protein size) and transferred to polyvinylidene dif-
luoride membranes [6]. Membranes were probed over-
night at 4  °C with the primary rabbit Aldh1a1 (Catalog 
No. # ab23375); klf4 (Catalog No. #4038S, Cell Signal-
ing): oct3/4 (Catalog No. #2750S, Cell Signaling); Nanog 
(Catalog No. #ab21624, abcam); α-fetoprotein (Catalog 
No. 3 2019-08, DAKO) and β-actin (Catalog No. ab8227, 
abcam) at a working dilution of 1:500, washed three 
times for 10  min each in Tris-buffered saline solution 
with 0.1  % Tween-20, and probed with secondary anti-
body (HRP-labeled, goat anti-rabbit IgG [H+L]; Abcam, 
Cambridge, MA, USA) for 1 h at room temperature at a 
working dilution of 1:2000. After incubation and three 
washes, immunostained proteins were detected using 
a chemiluminescence kit (Thermo Scientific, Waltham, 
MA, USA). To confirm equal loading, membranes were 
re-probed with beta-actin antibody. All experiments 
were repeated at least three times.
Results
All the rabbits that were implanted with VX2 liver tumor 
cells developed solid tumors. Histological analysis of 
the masses using H&E staining revealed well differenti-
ated atypical epitheliod tumors that were locally invasive 
and demonstrated choriodal distribution. These tumors 
are necrotic but have minimal inflammatory infiltration 
(Fig. 1a, b). We sorted tumor cells were sorted into dif-
ferent populations based on ALDH1 activity. The enzyme 
activity of the sorted ALDH-positive VX2 cell popula-
tion was greater than 50  %, but for our study, we used 
the brightest 4.39  % of the total cancer cell population. 
Results are presented as percentages of ALDH bright 
cells or as ratios of mean fluorescence intensities (MFI) 
as compared with control cells incubated with DEAB 
(Fig. 2).
To characterize the stemness of derived VX2 tumors, 
we performed semi-quantitative as well as real time PCR 
on samples from the tumors and tissues from normal rab-
bit liver. We demonstrated that VX2 tumors have higher 
expression of cancer stem cell markers such as AlDH1A1 
and CD44 in comparison to normal rabbit liver cells 
(Fig. 3). As these tumors are the first generation of tumors 
cells explanted from the rabbit, we speculated that the 
Fig. 1 Histological analysis of rabbit hepatic VX2 tumors. a Overview of the left lateral liver lobe showing the tumor (black arrow) and areas of 
necrosis (yellow arrow); 10× magnification. b 400× magnification of a section of the tumor showing necrotic and normal hepatocytes
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stem cell markers should be expressed significantly in 
these tumors. In accordance with the hypothesis, we veri-
fied that expression of stemness and pluripotent mark-
ers oct3/4, nanog and klf4 were overexpressed in VX2 
tumors (Fig.  3). We also observed the overexpression 
of differentiation marker nestin in VX2 tumors in com-
parison to normal rabbit liver (Fig. 3). Additionally, real 
time PCR analysis of the same samples using syber-green 
demonstrated the significant change (p > 0.05) (Fig. 4) in 
the expression of the genes (Fig.  3). Next, we validated 
gene expression of the stemness markers by performing 
western blot (Fig.  5) and immunofluorescence (Fig.  6). 
We showed that cancer stem cell markers (AlDH1A1, 
CD44) and the differentiation marker α-fetoprotein were 
upregulated in VX2 tumor cells (Fig. 5). The same extent 
of upregulation was observed in stemness markers (klf4, 
oct3/4 and nanog) in VX2 tumors in comparison to nor-
mal rabbit liver (Fig. 5).
Discussion
It has been established that CSCs play a critical role in 
the development of cancer. According to the CSC theory, 
not all cells in a tumor are equal; tumors are heterogene-
ous and many include the rare population with atavistic 
stem cell properties. These cells possess unique survival 
mechanisms and distinctive properties, such as the 
Fig. 2 Aldefluor flow cytometry-based assay to identify cells with high ALDH1 activity in the rabbit VX2 liver cancer model. The top panels show the 
histograms of Aldefluor fluorescence with (left) and without (right) the addition of DEAB, an ALDH activity inhibitor. The gate demonstrates shifting 
of cells with high ALDH activity (right). The other two gates show the light scatter pattern and the viable cells based on PI exclusion. The gating 
strategy for DEAB and ALDH demostrated in Additional files 1 and 2
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capacity to self-renew and differentiate, and also possess 
the capacity to proliferate following a prolonged period 
of quiescence. Our goal in these studies was to validate 
the VX2 orthotopic model by demonstrating the pres-
ence of CSCs in situ.
ALDH1 activity has been used as a functional stem 
cell marker to isolate CSCs in different types of cancers 
[36]. We found that ALDH1 was highly expressed in a 
4.39 % population of cells in the rabbit VX2 liver cancer 
model, as determined using Aldefluor flow cytometry 
and validated with immunohistochemical and western 
blot analyses. IHC analysis demonstrated the localization 
of ALDH-positive cells in the cytoplasm. These findings 
suggest that ALDH1 is highly expressed in the cyto-
plasm of the rabbit VX2 tumor (Fig. 6). The frequency of 
expression of ALDH1 and the localization of the activity 
are consistent with many previous reports that demon-
strate that the CSC population is small, usually account-
ing for only a fraction of all tumor types [37]. Collectively, 
the data produced in this study demonstrate that ALDH1 
is a marker for VX2 CSCs. Characterization of the func-
tionality of these markers will be performed in future 
studies in our laboratory.
Our findings show that an Aldefluor–FACS assay can 
successfully separate ALDH1-positive cells. Although 
more characterization of these cells is required, our work 
is a promising first step in development of a novel model 
Fig. 3 Analysis of mRNA expression. RNA were extracted from VX2 
tumors and from normal rabbit liver cells as a control. a Semi-quan-
titative RT-PCR expression analysis revealed that VX2 tumors have 
higher levels of cancer stemness markers (nestin, klf4, nanog, oct3/4, 
Nanog,CD44 and Aldh1a1) in comparison to normal liver cells. b 
Real-time PCR using Ssofast Evagreen demonstrated similar trend of 















































































































































Fig. 4 Group average expression of mRNA of stem cell markers (n = 3/group)
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for studying role of CSC in cancer therapy, resistance 
and recurrence. Because ALDH1-positive cells are viable 
and selectable on the basis of their fluorescence, they are 
readily available for stem cell studies. To the best of our 
knowledge, this is the first report for ALDH expression in 
the rabbit VX2 liver cancer model.
Expression of ALDH, especially the ALDH1A1 and 
ALDH3A1 isoforms, has been observed in normal cells 
as well as in CSCs. Expression seems to correlate with 
resistance to chemotherapy [38]. The high expression 
levels of ABC transporters and ALDH enzymes that have 
been found in CSCs suggest that these molecules can 
cooperate in the development of drug resistance in can-
cers. For example, ALDH1 overexpression has been posi-
tively associated with aggressive biological behavior of 
many cancer types, poor prognosis for patients, and drug 
resistance [7]. Therefore, the finding that ALDH1 over-
expression in VX2 tumors promotes the idea that this 
model may be useful to study chemoresistance. However, 
further characterization will be necessary to validate the 
utility.
Our findings indicate that Aldefluor-based sorting of 
rabbit VX2 tumor cells could allow for CSC enrichment. 
They also support the validity of using the rabbit VX2 
tumor model to study human hepatocellular carcinoma 
and provide concrete evidence that ALDH1 is expressed 
by and can be a functional marker in rabbit VX2 tumors. 
Our group has previously shown enhanced expression of 
ALDH1 in pig model of hepatocellular carcinoma using 
microarray expression and quantitative real time RT-PCR 
(Gehlot et al., unpublished). This novel finding that rab-
bit VX2 tumors have ALDH1 activity clarifies the utility 
of an important tool for understanding and identifying 
bipotential hepatic stem cells in a relevant large-animal 
model. Such understanding holds promise for devel-
opment of new therapeutics for a wide range of liver 
pathologies, ranging from congenital metabolic diseases 
to end-stage liver cirrhosis to hepatocarcinogenesis. This 
newly characterized model should enhance the ability to 
rapidly translate future studies for clinical application.
Conclusion
Our study results showed that we have identified and 
characterized the stemness of ALDH1A1 cells in rab-
bit VX2 liver cancer model. We demonstrated that VX2 
tumors have higher expression of cancer stem cell mark-
ers such as AlDH1A1 and CD44 in comparison to normal 
rabbit liver cells. The purpose of this study is to summa-
rize the role of stem like cell population in rabbit VX2 
liver tumor to discuss current attempts of cancer stem 
cell targeting.
Most of the animal models currently available to study 
HCC are rodent models, which lack clinical relevance. 
This study represents the first report of ALDH activity 
in rabbit hepatic VX2 cancer model and demonstrates 
utility of the model as a tool for understanding and iden-
tification of bipotential hepatic stem cells in a relevant 
large-animal system. Based on these findings, we propose 
that the rabbit VX2 model may be useful for identify-
ing new therapeutic treatments for a wide range of liver 
pathologies, including ranging from congenital metabolic 
Fig. 5 Analysis of protein expression by western blot. Proteins were 
extracted from VX2 tumors and from normal rabbit liver cells as a 
control. a β-actin expression was used as reference level. VX2 tumors 
expressed very high levels of stemness marker (CD44, klf4, oct3/4, 
nanog and Aldh1a1) in comparison to normal liver cells. Higher 
expression of cell differentiation marker α-fetoprotein in VX2 tumors 
in comparison to liver cells revealed that tumors from VX2 cells are 
well differentiated. b Quantification of protein expression in VX2 
tumors and in normal liver cells
ALDH-Negave Control ALDH staining 
ALDH : IHC
Fig. 6 Immunoflourescent photomicrographs demonstrating 
cytoplasmic distribution of ALDH (red) in situ. The negative control 
imaged without the addition of the primary antibody
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diseases, end-stage liver cirrhosis, and hepatocarcinogen-
esis. The use of this model may enhance the translation 
of novel therapeutics for clinical application. Emerging 
therapeutic tools based on specific properties and func-
tions of these subpopulations of cells inside the bulk of a 
tumor is crucial for improved clinical outcomes.
Statistical analysis
Results were presented as the mean and standard error 
of the mean (SEM). Data analysis was with GraphPad 
Prism software version 6. Pairs of data were analyzed by 
unpaired t test assuming unequal variance. Statistical sig-
nificance was defined as p < 0.05 unless stated otherwise.
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